Skip to content
Yescarta(axicabtagene ciloleucel)
Yescarta (axicabtagene ciloleucel) is a gene pharmaceutical. Axicabtagene ciloleucel was first approved as Yescarta on 2017-10-18. It has been approved in Europe to treat follicular lymphoma and large b-cell lymphoma diffuse.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Yescarta
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Axicabtagene ciloleucel
Tradename
Proper name
Company
Number
Date
Products
Yescartaaxicabtagene ciloleucelGilead SciencesA-125643 RX2017-10-18
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
yescartaBiologic Licensing Application2021-04-28
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
axicabtagene ciloleucel, Yescarta, Kite Pharma Inc.
2029-04-01Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX70: Axicabtagene ciloleucel
HCPCS
Code
Description
Q2041
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphomaD01639328——110
Large b-cell lymphoma diffuseD016403C83.345——18
Follicular lymphomaD008224C8223———4
Non-hodgkin lymphomaD008228C85.922———3
Cytokine release syndromeD000080424D89.83—2———2
Neurotoxicity syndromesD020258G92—1———1
Hematologic neoplasmsD019337—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.91————1
Hiv infectionsD015658EFO_0000764B201————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0————22
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAXICABTAGENE CILOLEUCEL
INNaxicabtagene ciloleucel
Description
Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.
Classification
Gene
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI1987398
ChEMBL IDCHEMBL3989989
ChEBI ID—
PubChem CID—
DrugBankDB13915
UNII IDU2I8T43Y7R (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Yescarta - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,376 documents
View more details
Safety
Black-box Warning
Black-box warning for: Yescarta
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,851 adverse events reported
View more details